Journal of Pediatrics Review

Published by: Kowsar

Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article

Javad Ghaffari 1 , * and Negar Ghaffari 2
Authors Information
1 Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2 Student of Medicine, Mazandaran University of medical sciences, Sari, IR Iran
Article information
  • Journal of Pediatrics Review: January 2018, 6 (1); e11507
  • Published Online: October 3, 2017
  • Article Type: Review Article
  • Received: June 21, 2017
  • Revised: July 21, 2017
  • Accepted: July 29, 2017
  • DOI: 10.5812/jpr.11507

To Cite: Ghaffari J, Ghaffari N. Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article, J Pediatr Rev. 2018 ;6(1):e11507. doi: 10.5812/jpr.11507.

Copyright © 2017, Journal of Pediatrics Review. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Discussion
  • 1. Ghaffari J, Navaeifar MR, Alizadeh-Navaei R. The prevalence of Eczema in Iranian children: A systematic review and meta-analysis. J Pediatr Rev. 2014;2(1):2-9. doi: 10.7508/jpr-v2-n1-2-9.
  • 2. Golpour M, Ghaffari J, Dabbaghzadeh A, Rezaiefard J. Management of children with atopic dermatitis: A narrative review. J Pediatr Rev. 2016;5(1). doi: 10.17795/jpr-7474.
  • 3. Caruso C, Gaeta F, Valluzzi RL, Romano A. Omalizumab efficacy in a girl with atopic eczema. Allergy. 2010;65(2):278-9. doi: 10.1111/j.1398-9995.2009.02153.x.
  • 4. Ghaffari J, Shahmohammadi S, Ashrafi H, Ranjbar AR, Ghaffari N. Omalizumab (Xolair) in children above 12 years with chronic urticaria: A review of literature. J Pediatr Rev. 2015;3(1). doi: 10.5812/jpr.152.
  • 5. Licari A, Marseglia A, Caimmi S, Castagnoli R, Foiadelli T, Barberi S, et al. Omalizumab in children. Paediatr Drugs. 2014;16(6):491-502. doi: 10.1007/s40272-014-0107-z. [PubMed: 25404353].
  • 6. Eguíluz-Gracia I, Robledo-Echarren T, Suárez-Fernández R, Fernández-Rivas M, Sánchez-Ramón S. Omalizumab for the treatment of atopic dermatitis. Clin Investig. 2015;5(2):121-36. doi: 10.4155/cli.14.108.
  • 7. Martin-Mateos MA. Monoclonal antibodies in pediatrics: use in prevention and treatment. Allergol Immunopathol (Madr). 2007;35(4):145-50. doi: 10.1157/13108225. [PubMed: 17663923].
  • 8. Ramirez del Pozo ME, Contreras Contreras E, Lopez Tiro J, Gomez Vera J. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol. 2011;21(5):416-7. [PubMed: 21905512].
  • 9. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol. 2007;120(5):1223-5. doi: 10.1016/j.jaci.2007.08.060. [PubMed: 17936892].
  • 10. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol. 2006;55(1):168-70. doi: 10.1016/j.jaad.2005.12.045. [PubMed: 16781320].
  • 11. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162(1):89-93. doi: 10.1159/000350486. [PubMed: 23816920].
  • 12. Lacombe Barrios J, Begin P, Paradis L, Hatami A, Paradis J, Des Roches A. Anti-IgE therapy and severe atopic dermatitis: a pediatric perspective. J Am Acad Dermatol. 2013;69(5):832-4. doi: 10.1016/j.jaad.2013.05.035. [PubMed: 24124824].
  • 13. Amrol D. Anti-immunoglobulin e in the treatment of refractory atopic dermatitis. South Med J. 2010;103(6):554-8. doi: 10.1097/SMJ.0b013e3181de0cf6. [PubMed: 20710140].
  • 14. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol. 2006;54(1):68-72. doi: 10.1016/j.jaad.2005.09.030. [PubMed: 16384758].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments